In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of Cryptococcus neoformans. Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Over...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Yamazumi, T., Pfaller, M. A., Messer, S. A., Houston, A., Hollis, R. J., Jones, R. N.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2000
Assuntos:	Susceptibility
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90171/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10991880/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.10.2883-2886.2000
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!